Herbal Composition Blocking SARS-CoV-2 Spike-ACE2 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and small molecule drugs have limited efficacy against mutated SARS-CoV-2 strains, and there is an urgent need for safe and effective herbal compositions to treat and prevent SARS-CoV-2 infections, including wild-type and mutant variants.
Innovation Solution
Development of herbal compositions, such as Kang Guan Receipt and Anti-epidemic formulas AN1 and AN2, utilizing extracts of specific herbs like Astragalus membranaceus, Atractylodes macrocephala, and Platycodon grandiflorum, to inhibit the interaction between viral spike glycoprotein and the ACE2 receptor, thereby blocking viral infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA vaccines are used to prevent SARS-CoV-2 infection, then immunity is provided against wild-type virus, but efficacy is reduced against mutated strains such as N501Y and E484K variants
Solution Approach 1:
The patent changes the chemical parameters of the antiviral agent by using herbal extracts with different molecular structures and mechanisms of action compared to mRNA vaccines. The herbal composition targets the spike protein-receptor binding interface with natural compounds that can adapt to various viral mutations, thereby maintaining efficacy against both wild-type and mutant strains.
Solution Approach 2:
The patent employs a composite herbal formulation containing multiple extracts (Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, and other traditional Chinese medicine components) that work synergistically. This composite approach provides broad-spectrum antiviral activity that can counteract multiple viral variants simultaneously, overcoming the limitation of single-target mRNA vaccines.
2Reliability
If small molecule drugs are developed to treat SARS-CoV-2, then direct antiviral effect is achieved, but clinical efficacy is poor as demonstrated by early quinine trials
Solution Approach 1:
The patent uses a composite herbal formulation rather than a single small molecule drug. The combination of multiple herbal extracts (Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, etc.) provides synergistic antiviral effects that have demonstrated better clinical efficacy than individual small molecule drugs like quinine in previous trials.
Solution Approach 2:
The herbal compounds act as natural intermediaries that block the interaction between the viral spike protein and the ACE2 receptor. These natural mediators have shown superior efficacy compared to synthetic small molecules, achieving both direct antiviral effect and acceptable clinical outcomes.
3Adaptability or versatility
If herbal compositions are used to treat SARS-CoV-2 infection, then broad spectrum activity against wild-type and mutant strains is achieved, but mechanism of action must be clearly defined
Solution Approach 1:
The patent extracts and isolates the active antiviral components from traditional herbal formulations. By identifying the specific compounds within Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, and other herbs that inhibit spike protein-receptor binding, the mechanism of action becomes detectable and measurable while maintaining broad-spectrum activity.
Data Source
AI summary
This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.